The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2)

Abstract

Thrombospondin (TSP)-1 and TSP-2 share similar structures and functions, including a remarkable antiangiogenic activity. We have previously demonstrated that a mechanism of the antiangiogenic activity of TSP-1 is the interaction of its type III repeats domain with fibroblast growth factor-2 (FGF2), affecting the growth factor bioavailability and angiogenic activity. Since the type III repeats domain is conserved in TSP-2, this study aimed at investigating whether also TSP-2 retained the ability to interact with FGF2. The FGF2 binding properties of TSP-1 and TSP-2 and their recombinant domains were analyzed by solid-phase binding and surface plasmon resonance assays. TSP-2 bound FGF2 with high affinity (Kd = 1.3 nM). TSP-2/FGF2 binding was inhibited by calcium and heparin. The FGF2-binding domain of TSP-2 was located in the type III repeats and the minimal interacting sequence was identified as the GVTDEKD peptide in repeat 3C, corresponding to KIPDDRD, the active sequence of TSP-1. A second putative FGF2 binding sequence was also identified in repeat 11C of both TSPs. Computational docking analysis predicted that both the TSP-2 and TSP-1-derived heptapeptides interacted with FGF2 with comparable binding properties. Accordingly, small molecules based on the TSP-1 active sequence blocked TSP-2/FGF2 interaction. Binding of TSP-2 to FGF2 impaired the growth factor ability to interact with its cellular receptors, since TSP-2-derived fragments prevented the binding of FGF2 to both heparin (used as a structural analog of heparan sulfate proteoglycans) and FGFR-1. These findings identify TSP-2 as a new FGF2 ligand that shares with TSP-1 the same molecular requirements for interaction with the growth factor and a comparable capacity to block FGF2 interaction with proangiogenic receptors. These features likely contribute to TSP-2 antiangiogenic and antineoplastic activity, providing the rationale for future therapeutic applications.

Resveratrol Improves Bnip3-Related Mitophagy and Attenuates High-Fat-Induced Endothelial Dysfunction

“…Therefore, an urgent need exists for hyperlipemia management. In the present study, we found that resveratrol improved endothelial function through sustaining endothelial cell viability, proliferation, and mobilization (Rusnati et al, 2019). Resveratrol treatment activated HIF1 and AMPK pathways, contributing to Bnip3 upregulation and mitophagy activation.…”

RETRACTED: Mammalian STE20-Like Kinase 2 Promotes Lipopolysaccharides-Mediated Cardiomyocyte Inflammation and Apoptosis by Enhancing Mitochondrial Fission

“…Briefly, we seeded 1 × 10 4 H9C2 cells per well in 96-well plates overnight followed by incubation with LPS for 24 h. Then, after removing the medium, fresh medium supplemented with 0.5 mg/ml MTT (Solarbio) was added and the cells were cultured for another 4 h. The medium was then removed and the formazan product formed in the cells was extracted with 100 μl dimethyl sulfoxide (DMSO; Beyotime; Farber et al, 2018). The absorbance was read at 570 nm using a microplate reader (Enzyme-linked Biotechnology, Shanghai, China) and cell viability in the experimental group was normalized to the control (Rusnati et al, 2019).…”

Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease

“…Anti-CD47 antibodies and small molecules that mimic the TSP binding site for bFGF are being tested in clinical trials, in preclinical models, or are under development for various diseases. 169,[178][179][180][181][182] Antagonists of these antiangiogenic TSP1 functions have not been tested with antagonists of TSP1's TGF-β activating function. Combined use of a variety of TSP1 functional antagonists could represent a multipronged approach to treating the complex pathogenesis of fibrosis.…”